Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Net Income (2021 - 2025)

Senti Biosciences has reported Net Income over the past 4 years, most recently at -$18.5 million for Q4 2025.

  • For Q4 2025, Net Income changed N/A year-over-year to -$18.5 million; the TTM value through Dec 2025 reached -$67.9 million, changed N/A, while the annual FY2025 figure was -$67.9 million, N/A changed from the prior year.
  • Net Income for Q4 2025 was -$18.5 million at Senti Biosciences, down from -$16.8 million in the prior quarter.
  • Over five years, Net Income peaked at $21.7 million in Q3 2023 and troughed at -$21.7 million in Q2 2022.
  • A 4-year average of -$7.8 million and a median of -$8.8 million in 2021 define the central range for Net Income.
  • Biggest five-year swings in Net Income: plummeted 997692.87% in 2022 and later skyrocketed 1028.2% in 2023.
  • Year by year, Net Income stood at -$3.9 million in 2021, then tumbled by 121.54% to -$8.5 million in 2022, then soared by 99.67% to -$28000.0 in 2023, then crashed by 66110.71% to -$18.5 million in 2025.
  • Business Quant data shows Net Income for SNTI at -$18.5 million in Q4 2025, -$16.8 million in Q3 2025, and -$16.5 million in Q2 2025.